AuthorMouseDoctor

Q&A June

This month is Royal Ascot so it is Horse racing time

Sculpture from the East end of London

Disclaimer: Please note that the opinions expressed here are those of the author and do not reflect the positions of the Barts and The London School of Medicine and Dentistry nor Barts Health NHS Trust or Queen Mary Univeristy of London.

Thank You, Your COVID Vaccine experiences

Experience with the COVID-19 AstraZeneca vaccination in people with multiple sclerosis.Allen-Philbey K, Stennett A, Begum T, Johnson AC, Dobson R, Giovannoni G, Gnanapavan S, Marta M, Smets I, Turner BP, Baker D, Mathews J, Schmierer K.Mult Scler Relat Disord. 2021 May 18;52:103028. doi: 10.1016/j.msard.2021.103028. Online ahead of print. Background: Some people with multiple sclerosis...

Saturday COVID Lunch

T cells responses in B cell response immunocompromised people This is not MS but I think it is telling us what is going to happen as I am seeing this over and over again. We can predict that people on CD20-depleting antibodies are going to make a poor anybody response, but a greater proportion of people will make a T cell response against the virus. It think the question is how many?. At present...

The Fourth eagle has landed

First we had fingolimod, then came siponimod, then oxazinimod and now we have ponesimod after the EMA approved it. These are all Sphingosine-1-phosphateone receptor modulators. Ponvory (ponesimod) is approved for the treatment of adult patients with relapsing multiple sclerosis (RMS) with active disease defined by clinical or imaging features. “Relapsing multiple sclerosis is an unpredictable and...

The causative link of EBV and MS explained?…ProfG will be happy

ProfG has been on an EBV crusade, but why or how does it cause/trigger MS? HLA-DRB1*15:01 is a coreceptor for Epstein-Barr virus, linking genetic and environmental risk factors for multiple sclerosis. Eur J Immunol 2021. The strongest genetic and environmental risk factors for multiple sclerosis (MS), an inflammatory central nervous system disease, are HLA-DRB1*15:01 and Epstein-Barr virus (EBV)...

Blog Essay: Mouse EAE is a T -cell disease….Discuss

It is exam times at university and if I was setting an exam for the London School of EAEers, this is the title I would give. OK it is supposed to be contentious. Maybe it is time to retire as that Mr Hyde keeps popping up As a card carrying EAEer I think I can comment on this one presented by NDG today and hope that it my constructive comments will get me into trouble with the EAE trade Union...

Tumour-like lesions 2 days after drinking fizzy pop.

I have to give a disclaimer that I have just made this up!…….No, I didn’t work for the BCC:-), but it could be a possibility that after drinking: Lip-smacking, ace-tasting, motivting, good, buzzing-cool, walking-high, living, evergiving, cool fizzing……pop…….yep I don’t want to say anything specific, in case I get sued for linking anything to...

Early Natalizumab treatment

No sooner has the dust from ProfGs survey settled. When you suggested that natalizumab first line may be a nice addition to UK MS treatment…..no sooner have we said ATTACKMS butDr.Foxy has come out with some data looking at early treatment with natalizumab….and guess what have low lesion numbers and disability is a good sign Natalizumab in Early Relapsing-Remitting Multiple Sclerosis:...

Saturday COVID Lunch

CD20-depleting antibodies and catching COVID-19 is reported to be bad news however In this study there were 9/258 people who got COVID and the conclusion was that “rituximab seems not to be safe enough during the pandemic”. This is a opinion. This could be countered other opinions, by the data from the Global Data Sharing approach where hundreds of CD20-treated people developed COVID...

Natalizumab and Fingolimod in real life studies

As you know I am not a neurologists and am not making any recommendations but this study looked at the real life effect of natalizumab and fingolimod as the two major migration inhibitors. Andersen JB et al. The effectiveness of natalizumab vs fingolimod – a comparison of international registry studies. MSARDS 2021. DOI: Background:Natalizumab and fingolimod were the first preparations...

Translate

Categories

Recent Posts

Recent Comments

Archives